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classical triad of symptoms: weakness, rash, Accepted 1 September 1994 and misery. Many children will respond well '4 Trial 1 6 1 g/kg for 2 days each month for 6 months 6 Trial 2 6 0 4 g/kg for 4 days each month for 6 months 6 to corticosteroid treatment. A starting dose of 1 mg/kg/day is used, gradually tapering off over 6-12 months, once a response has occurred. High dose steroids have no benefit over this low dose regimen and carry a risk of significant morbidity, including osteoporosis, myopathy, hypertension, gastrointestinal symptoms, and obesity.1 2 Even with low dose steroids there may be significant complications.
Further immunosuppression may be required in patients with refractory disease. Azathioprine has been a valuable agent in juvenile dermatomyositis (dose 2-5 mg/kg/day). Although it is rather slow in action,3 4 it has relatively few side effects. Its main benefit has been to allow a reduction in steroid dose. Low dose cyclosporin (starting dose 4 mg/kg/day) has proved a useful additional treatment in refractory juvenile dermatomyositis.5 It acts principally by T cell suppression. The main side effect is on the kidney, but with careful monitoring this is uncommon.
Some children require additional immunosuppression when disease symptoms remain uncontrolled, and have responded to methotrexate or cyclophosphamide. Plasmapheresis has also been used on rare occasions, but it is not a recommended treatment. 6 The use of immunoglobulin in adults with polymyositis and dermatomyositis has shown promising results in steroid sparing and appears to be a safe alternative to cytotoxic treatment.7 More recently, a controlled trial of high dose intravenous immunoglobulin in 15 adults with treatment resistant dermatomyositis showed convincing improvement in muscle strength in nine of 12 treated individuals and minor improvement in two, as compared with none of the placebo group. 8 There has been reported benefit in paediatric autoimmune disorders, particularly Kawasaki disease9-1 and systemic juvenile arthritis.12 With the relative rarity of juvenile dermatomyositis, clinical trials of intravenous immunoglobulin have so far been uncontrolled and largely anecdotal.13 14 It has produced some benefit in a few children with persistent disease or complications of standard treatment (table 1) .
In a trial of five children by Lang et al, a dose of 1 g/kg immunoglobulin was given for two days each month for nine months.'3 All five children showed improvement in muscle strength and skin rash, and their dose of prednisolone was reduced or stopped. Barron et al reported two small trials, one using 1 g/kg for two days and the second using 04 g/kg for four days each month for six months. '4Again, all children showed some improvement in Of the nine patients receiving intravenous immunoglobulin, the age of onset of the dermatomyositis ranged from 1 9 to 11-0 years (mean age 7-8 years). The age range at which intravenous immunoglobulin was given was 8-5 to 11 9 years with a mean age of 106 years.
Most patients were over a year into their illness, ranging from 11 months from the initial presentation to five and a half years, with the exception of one patient who had a late relapse at 10 years after initial illness. The mean time from onset of disease to treatment with immunoglobulin was 2-8 years.
Two children had received drugs additional to the standard triple treatment. One had cyclophosphamide alone, the other received methotrexate followed by cyclophosphamide. The latter child suffered neutropenia while on cyclophosphamide; other side effects were related to corticosteroids. All the children on corticosteroids had experienced some side effects, particularly cushingoid features with weight gain. Three developed hypertension requiring treatment, six developed osteoporosis, four growth suppression, and one avascular necrosis of the femoral head.
ASSESSMENT OF MUSCLE FUNCTION
All children given intravenous immunoglobulin were formally assessed on the day before infusion and on one occasion within two weeks after infusion. Myometry, using a hand held Penny and Giles myometer, was performed in 32 muscle groups. The best reading of three attempts was taken. The results of myometry have been collated and are simplified to total the score in five muscle groups for this assessment: neck flexors, right and left knee extension, shoulder abduction, hip flexion, and hip abduction. The motor ability score of 20 functions on a two point scale'6 and, when feasible, a walking time for 28 feet (8-5 m) was assessed on each clinical visit. Due to the wide geographical distribution of the patients and consequent long journeys, they were not all formally assessed after every treatment. In some cases a subjective report of their progress had to be taken when they could not attend personally for review. This would be their perceived improvement in strength, change in rash, and general mood.
Results
The number of courses given to individual children varied according to their clinical condition and ranged from one, in a girl who tolerated intravenous treatment very poorly, to six, with a mean of four. The time interval between treatments also varied with the severity of the condition, ranging from four to 10 weeks (mean 5-5 weeks). Most of the children required repeat treatment at 4-6 week intervals.
A total of 33 courses of immunoglobulin were given in the nine children. Of these we have formal before and after treatment assessment in 20 courses (table 2). In these 20 there was improvement in 16. In these 20 paired assessments, the mean myometry score in the five selected muscle groups showed an improvement of 2-85. Using the Wilcoxon doses (fig 2) .
As a result of intravenous immunoglobulin infusion in the four children with relapses on high dose treatment, one child, on cyclosporin and prednisolone, was maintained on the same steroid dose despite relapse, two children on triple treatment had their dose of prednisolone slowly reduced (fig 3) , and the fourth child, on cyclosporin alone, avoided restarting steroids.
In the two children who were weak on their current treatment, one girl on high dose prednisolone made marked clinical improvement and the prednisolone dose could be reduced. The other boy on cyclosporin SIDE 
EFFECTS
Many children complained of a mild headache after treatment with the initial dose of 2 g/kg given over three days. This was severe in four of the nine after one course or more. Two suffered diarrhoea after treatment, one severe nausea, and one fever.
As with the variability in clinical response, we found that side effects may occur after one course of treatment but not another. In general side effects did not correlate with the clinical response. However, we subsequently found that on an attenuated regimen of 2 g/kg spread over five days instead of three none of these side effects occurred.
Discussion
The aetiology of juvenile dermatomyositis remains unknown, although infectious agents have been identified as potential precipitating causes. 17 The fact that the disease shows an association with particular HLA class I and II antigens, and that specific autoantibodies have been found, suggest that juvenile dermatomyositis has an immunological basis. It was on the strength of this, and the action of immunoglobulin in other autoimmune disorders, that its potential use was established. Intravenous immunoglobulin has many effects on immunological function, but the actual mechanism of action is unknown. There have been various hypotheses as to its therapeutic effect. These have included the inhibition or binding of activated complement to target cells'8 and reduced complement deposition,'9 therefore modifying complement mediated tissue damage. There may be a wider effect on antibody production, the rise in immunoglobulin concentrations after treatment causing down regulation of immunoglobulin production.20 It has also been suggested that antibodies in intravenous immunoglobulin may neutralise autoantibodies in the patient.2' Other potential mechanisms of immunomodulation and inhibition of cytokine secretion has also been proposed.22
Whichever the mechanism of action, our results suggest that intravenous immunoglobulin has some influence on the course of disease in some selected cases of juvenile dermatomyositis. However, the response has been inconsistent and unpredictable, both between patients and also between courses in the same patient. This may possibly be due to variation in the donor pools of different batches of intravenous immunoglobulin.
We found the side effects too frequent and severe for the children to tolerate the intensive three day course, so would recommend the five day regimen (using the same total dose of 2 g/kg), which reduced the incidence of headache, nausea, and gastrointestinal disturbance.
The use of immunoglobulin has been of value in the management of children with juvenile dermatomyositis, particularly in a role of steroid sparing and as an alternative to immunosuppression. On the available data we would not at present recommend it as a first line of treatment, but still prefer low dose (1 mg/kg/day) prednisolone for induction of remission in view of its consistent effectiveness.
It is difficult to assess, in a single centre, the overall application of intravenous immunoglobulin in view of the limited number of new cases seen each year. Many patients referred to our tertiary centre have already had an initial treatment course of prednisolone, often at a higher dose than we would recommend. A multicentre trial would undoubtedly throw more light on the overall possibilities of therapeutic management, including the use of immunoglobulin as an adjunct to established regimens.
